KOREA WHO
-
-
CEO of Yuhan Corporation
Cho Wook-je
Sales Expert with 30 Years in Sales, Focused on New Drug Development and Business Expansion
-
Last Updated on Dec 4, 2024
-
CEO of Yuhan Corporation
Copy Url : https://www.koreawho.com/profile/ChoWookje- Life Summary
Cho Wook-je is the President and CEO of Yuhan Corporation.
To achieve the goal of ranking among the top 50 global pharmaceutical companies by 2026, he is focusing on developing new drugs such as "Leclaza," a treatment for non-small cell lung cancer.
He was born on January 2, 1955.
Cho graduated from Masan High School in Gyeongnam and went on to study Agricultural Chemistry at Korea University.
After joining Yuhan Corporation, he worked exclusively in the sales department for 30 years, establishing himself as an expert in sales and marketing.
In 2021, he succeeded the former President and CEO Lee Jeong-hee and was appointed as the President and CEO.
In March 2024, Cho was successfully re-elected during the annual shareholders’ meeting, extending his term until March 2027.
#Yuhan #ChoWookje #pharmaceuticals #Leclaza #non-smallcelllungcancer #CEO #SouthKorea #drugdevelopment #KoreaUniversity #globalpharma
To achieve the goal of ranking among the top 50 global pharmaceutical companies by 2026, he is focusing on developing new drugs such as "Leclaza," a treatment for non-small cell lung cancer.
He was born on January 2, 1955.
Cho graduated from Masan High School in Gyeongnam and went on to study Agricultural Chemistry at Korea University.
After joining Yuhan Corporation, he worked exclusively in the sales department for 30 years, establishing himself as an expert in sales and marketing.
In 2021, he succeeded the former President and CEO Lee Jeong-hee and was appointed as the President and CEO.
In March 2024, Cho was successfully re-elected during the annual shareholders’ meeting, extending his term until March 2027.
#Yuhan #ChoWookje #pharmaceuticals #Leclaza #non-smallcelllungcancer #CEO #SouthKorea #drugdevelopment #KoreaUniversity #globalpharma
- Related News
- Life Summary
- Career Highlights & Challenges
- · Domestic Pharmaceutical Company Expected to Reach KRW 2 Trillion in Sales for the First Time
- · 'From 2025, One Technology Transfer Annually' as Part of Value Enhancement Plan
- · Yuhan Corporation Pushes for Kosdaq Listing of Subsidiary ImmuneOncia
- · Expanding R&D to Discover the Next "Leclaza"
- · Expanding Investment in Cosmetics Business for Diversification
- · Leclaza Crosses U.S. FDA Approval Milestone After Six Years, First Domestic Oncology Drug
- · 'Leclaza Approved for Health Insurance Coverage as First-Line Therapy in South Korea'
- · Investing in Microbiome Drug Development and Strengthening Probiotics Expertise
- · 'Pursuing mRNA Platform Technology Development'
- · Accelerating Global Clinical Trials for NSCLC Treatment Leclaza
- · Exploring New Businesses: Pet Care and Wearable Medical Devices
- · Rising from Entry-Level Employee to CEO of Yuhan Corporation
- · History of Yuhan Corporation
- Vision and Goals
- Market and Social Evaluation
- Notable Incidents & Legal Affairs
- Professional Timeline
- Educational Background
- Additional Information
- Notable Quotations
- Infographic & Photos